Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Delpacibart etedesiran by Avidity Biosciences for Myotonic Dystrophy: Likelihood of Approval
Delpacibart etedesiran is under clinical development by Avidity Biosciences and currently in Phase III for Myotonic Dystrophy. According to GlobalData,...
Delpacibart zotadirsen by Avidity Biosciences for Duchenne Muscular Dystrophy: Likelihood of Approval
Delpacibart zotadirsen is under clinical development by Avidity Biosciences and currently in Phase II for Duchenne Muscular Dystrophy. According to...
Risk adjusted net present value: What is the current valuation of Avidity Biosciences's AOC-1020?
AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy...
Risk adjusted net present value: What is the current valuation of Avidity Biosciences's Delpacibart etedesiran?
Delpacibart etedesiran is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Myotonic Dystrophy....